YLYue Liu

Yue Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yue Liu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multimorbidity in elderly patients with or without T2DM: A real-world cross-sectional analysis based on primary care and hospitalisation data

    by Yang Li, Shasha Geng, Huixiao Yuan, Jianli Ge, Qingqing Li, Xin Chen, Yingqian Zhu, Yue Liu, Xiaotong Guo, Xiaoli Wang, et al.

    Type 2 diabetes mellitus (T2DM) increases the global economic burden and risk of premature death [1]. Widespread use of medications such as aspirin and angiotensin-converting enzyme inhibitors (ACEIs) has progressively reduced the affected population’s risk of cardiovascular death and increased their life expectancy, leading to a higher likelihood of other age-related chronic diseases [2]. Many […]


  • Open Access

    Nephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study

    by Shasha Geng, Yang Li, Jianli Ge, Yue Liu, Qingqing Li, Xin Chen, Yingqian Zhu, Xiaotong Guo, Huixiao Yuan, Xiaoli Wang, et al.

    Objectives: This study aimed to investigate the nephroprotective effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes mellitus (T2DM) and hypertension based on real-world clinical data. The study aimed to provide a theoretical basis for evidence-based pharmacological treatment of chronic kidney disease in this population. Methods: The 'Health Cloud' platform of the Shanghai Municipal Health Commission was employed to identify and screen elderly patients with T2DM and hypertension. The propensity score matching cohort was further constructed to estimate the effect of SGLT2i on the risk of rapid decline in renal function (triangle eGFR <=-5 ml/min/1.73 m(2) or triangle eGFR%<=-5%). Multiple sensitivity analyses were conducted to assess the robustness of the results. Results: After propensity score matching, no significant differences of covariates were identified between the SGLT2i and non-SGLT2i groups. The results of multivariate logistic models demonstrated a consistent and inverse correlation between SGLT2i use and the risk of rapid eGFR decline, whether defined as triangle eGFR <=-5 ml/min/1.73 m(2) (OR = 0.60, 95% CI:0.38-0.96) or triangle eGFR%<=-5%(OR = 0.57, 95% CI:0.37-0.89). In the stratification of renin-angiotensin system inhibitor (RASi) treatment, SGLT2i was associated with a lower risk of rapid eGFR decline in the RASi group (all ORs < 1, p < 0.05), with no interaction between SGLT2i and RASi (all P for interaction > 0.05) detected. Conclusions: SGLT2i significantly reduced the risk of rapid eGFR decline in elderly patients with T2DM and hypertension, but the synergistic effect with RASi remains unclear.